Dandan Hu , Jialin Zhao , Miaoqing Wu , Ying Zhou , Beile Lyu , Chaoqun Xu , Chao Huang , Zixuan Su , Hui Zhang , Jintao Guo , Weiwei Tang , Gong Chen , Qiyuan Li
{"title":"微生物相互作用诱导结直肠癌错配修复缺陷的突变特征并与EPPK1突变相关","authors":"Dandan Hu , Jialin Zhao , Miaoqing Wu , Ying Zhou , Beile Lyu , Chaoqun Xu , Chao Huang , Zixuan Su , Hui Zhang , Jintao Guo , Weiwei Tang , Gong Chen , Qiyuan Li","doi":"10.1016/j.canlet.2025.217807","DOIUrl":null,"url":null,"abstract":"<div><div>To better understand the impact of microbial interactions on the clonal evolution of colorectal cancer (CRC), we conducted high-resolution profiling of the gut microbiome of 101 treatment-naïve primary CRC patients using nanopore sequencing. We performed an integrated analysis of microbiome and tumor exome data to identify symbiotic microbes that interactively influence the mutational processes and the subsequent clonality of CRC. Our results suggested that <em>Dialister pneumosintes</em> and <em>Fusobacterium animalis</em> were both associated with somatic <em>EPPK1</em> mutations and promote <strong>SBS6</strong> (mismatch repair deficiency, dMMR) activity. Notably, we showed that the symbiotic architecture of <em>Dialister pneumosintes</em> and <em>Fusobacterium animalis</em> undergoes significant changes with the mutational status of <em>EPPK1</em>. In addition, we identified specific metabolic pathways involving key metabolites that potentially mediate microbial interactions in CRC. These findings provide new insights into the interplay between the gut microbiome and the mutation landscape of colorectal cancer, thereby informing the clonal evolution of CRC and new strategies for precision medicine.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"625 ","pages":"Article 217807"},"PeriodicalIF":9.1000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Microbial interactions induce the mutational signature of mismatch repair deficiency in colorectal cancer and associated with EPPK1 mutations\",\"authors\":\"Dandan Hu , Jialin Zhao , Miaoqing Wu , Ying Zhou , Beile Lyu , Chaoqun Xu , Chao Huang , Zixuan Su , Hui Zhang , Jintao Guo , Weiwei Tang , Gong Chen , Qiyuan Li\",\"doi\":\"10.1016/j.canlet.2025.217807\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>To better understand the impact of microbial interactions on the clonal evolution of colorectal cancer (CRC), we conducted high-resolution profiling of the gut microbiome of 101 treatment-naïve primary CRC patients using nanopore sequencing. We performed an integrated analysis of microbiome and tumor exome data to identify symbiotic microbes that interactively influence the mutational processes and the subsequent clonality of CRC. Our results suggested that <em>Dialister pneumosintes</em> and <em>Fusobacterium animalis</em> were both associated with somatic <em>EPPK1</em> mutations and promote <strong>SBS6</strong> (mismatch repair deficiency, dMMR) activity. Notably, we showed that the symbiotic architecture of <em>Dialister pneumosintes</em> and <em>Fusobacterium animalis</em> undergoes significant changes with the mutational status of <em>EPPK1</em>. In addition, we identified specific metabolic pathways involving key metabolites that potentially mediate microbial interactions in CRC. These findings provide new insights into the interplay between the gut microbiome and the mutation landscape of colorectal cancer, thereby informing the clonal evolution of CRC and new strategies for precision medicine.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"625 \",\"pages\":\"Article 217807\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S030438352500374X\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S030438352500374X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Microbial interactions induce the mutational signature of mismatch repair deficiency in colorectal cancer and associated with EPPK1 mutations
To better understand the impact of microbial interactions on the clonal evolution of colorectal cancer (CRC), we conducted high-resolution profiling of the gut microbiome of 101 treatment-naïve primary CRC patients using nanopore sequencing. We performed an integrated analysis of microbiome and tumor exome data to identify symbiotic microbes that interactively influence the mutational processes and the subsequent clonality of CRC. Our results suggested that Dialister pneumosintes and Fusobacterium animalis were both associated with somatic EPPK1 mutations and promote SBS6 (mismatch repair deficiency, dMMR) activity. Notably, we showed that the symbiotic architecture of Dialister pneumosintes and Fusobacterium animalis undergoes significant changes with the mutational status of EPPK1. In addition, we identified specific metabolic pathways involving key metabolites that potentially mediate microbial interactions in CRC. These findings provide new insights into the interplay between the gut microbiome and the mutation landscape of colorectal cancer, thereby informing the clonal evolution of CRC and new strategies for precision medicine.
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.